Mediso has introduced its new AnyScan TRIO SPECT/CT, TheraMAX scanner at the European Association of Nuclear Medicine (EANM) annual meeting, held in Hamburg, Germany. The TheraMAX scanner is designed to meet the growing demands of theranostic imaging, which combines diagnostic imaging with targeted radionuclide therapies.

The TheraMAX scanner is equipped with three large-surface detectors, offering up to five times the detection area of traditional 12-detector CZT systems. It is engineered to handle isotopes such as 177Lu, 212Pb, 131I, and 225Ac, which are used in therapies emitting high-energy gamma photons, alpha, and beta particles. The system’s 15.9mm thick NaI crystals and advanced detector arrangement provide high sensitivity and PET-like image resolution.

With a reported 300% sensitivity increase over conventional dual-detector systems, the TheraMAX enables faster, more precise whole-body SPECT/CT scans. Its applications are particularly strong in cardiology and neurology, where the system’s novel multi-pinhole technology and high-density sensor arrangement improve both speed and image clarity.

The first global installation of the TheraMAX took place at the University Hospital Regensburg in Germany. According to professor Dr. Dirk Hellwig, head of the hospital’s nuclear medicine department, the system has enhanced their diagnostic capabilities and improved theranostic workflows.

Mediso, a Hungary-based molecular imaging manufacturer, has been in operation for over 35 years, with more than 1,400 clinical and 350 preclinical systems installed globally. The company’s portfolio includes multimodality imaging devices and advanced evaluation software.